Metadata record for the manuscript: Circulating tumor DNA and magnetic resonance imaging to predict neoadjuvant chemotherapy response and recurrence risk

<b>Summary</b><br>

This
metadata record provides details of the data supporting the claims of the
related manuscript: “Circulating tumor DNA and magnetic
resonance imaging to predict neoadjuvant chemotherapy response and recurrence
risk”.

The
related study investigated whether serial measurements of circulating tumor DNA
(ctDNA) and functional tumour volume (FTV) by magnetic resonance imaging (MRI)
can be combined to improve prediction of pathologic complete response (pCR) and
estimation of recurrence risk in early breast cancer patients treated with
neoadjuvant chemotherapy (NAC).

Type of data:
ctDNA, FTV and clinicopathologic data

Subject of
data: <i>Homo sapiens</i>

Sample size:
84 women

Population
characteristics: early breast cancer patients treated with NAC

Recruitment:
women with high-risk (stage II or III) early breast cancer from the I-SPY 2
TRIAL who had paired ctDNA and FTV data

Trial
registration number: I-SPY 2 TRIAL (NCT01042379)

<b>Data
access</b>

Clinicopathologic,
ctDNA, and FTV data that support the findings of this study are available in Supplementary
Table 5, which is available in the Supplementary Files of the article.

Clinicopathologic
and response data have also been deposited in NCBI’s <i>Gene </i><i>Expression Omnibus</i> and
are accessible through GEO SuperSeries accession number https://identifiers.org/geo:GSE150576.

The full MRI
data will be deposited in <i>The Cancer
Imaging Archive</i> (TCIA) and the accession ID is anticipated to be released in
mid-2021. When the data become available, the metadata record associated with the
group’s previous article (https://doi.org/10.6084/m9.figshare.12912191)
will be updated to include the TCIA data DOI. Prior to release, MRI data
queries can be directed to the corresponding authors (WL and NH).

<b>Corresponding author(s) for this study</b>

Mark
Jesus M. Magbanua ([e-mail])

Wen
Li ([e-mail])

Nola
Hylton ([e-mail])

Laura
van ‘t Veer ([e-mail])

<br>
<b>Study approval </b>

All
participating sites (University of California San Francisco, MD Anderson Cancer
Center; Loyola University, University of California San Diego, University of
Alabama at Birmingham, Swedish Cancer Institute, University of Chicago Medical
Center, University of Colorado Denver, University of Texas Southwestern, Oregon
Health &amp; Science University, Georgetown University, University of
Pennsylvania, University of Southern California, Cancer Therapy Evaluation
Program, Inova Health System, Mayo Clinic, University of Arizona, Masonic
Cancer Center, University of Minnesota) received approval from an institutional
review board. All patients signed informed consent to allow research on and use
of their biospecimen samples.